Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Annual Revenue ($)
Medtronic revenue was $30.12 b in FY, 2021
Quarterly Revenue ($)
| FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | |
|---|---|---|---|---|
| Revenue | $29.95 b | $30.56 b | $28.91 b | $30.12 b |
| Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.38 b | $7.48 b | $7.55 b | $7.49 b | $7.71 b | $7.72 b | $6.51 b | $7.65 b | $7.78 b | $7.99 b | $7.85 b | $7.76 b |
Revenue Breakdown
Business Segment
Medtronic revenue breakdown by business segment: 8.0% from DIABETES GROUP, 29.0% from MEDICAL SURGICAL, 27.2% from NEUROSCIENCE and 35.8% from CARDIOVASCULAR
| FY, 2021 | FY, 2020 | FY, 2019 | FY, 2018 | |
|---|---|---|---|---|
| BRAIN THERAPIES | $2.14 m | |||
| DIABETES GROUP | $2.41 m | $2.37 m | $2.39 m | $7.74 m |
| CARDIAC AND VASCULAR GROUP | $10.47 m | $11.51 m | $11.35 m | |
| RESPIRATORY, GASTROINTESTINAL, & RENAL | $8.72 m | |||
| MINIMALLY INVASIVE THERAPIES GROUP | $8.35 m | $8.48 m | ||
| RESTORATIVE THERAPIES GROUP | $7.73 m | $8.18 m | ||
| MEDICAL SURGICAL | $8.74 m | |||
| NEUROSCIENCE | $8.2 m | |||
| CARDIOVASCULAR | $10.77 m |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.